Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology.
Coming from a clear OTC focus in the last 15 years, we have decided to expand the applications of iota-carrageenan in the field of viral infectious diseases and focus our Marinosolv-based pipeline on therapies for immune disorders as we aim to provide physicians and patients with powerful therapies to significantly improve the patients' quality of life.
MAM-1004-1/Budesolv is a nasal spray containing the corticosteroid budesonide solubilized with Marinomeds proprietary Marinosolv solubilization technology. Budesolv is intended to treat severe allergic rhinitis and has met all endpoints in a phase III clinical trial.
In addition to Budesolv, Marinomed has developed a dissolved fluticasone propionate formulation that has potential in the allergy area similar to Budesolv.
MAM-1003-1/Tacrosolv is a topically applied, anti-inflammatory and immunomodulating ophthalmic solution, containing Tacrolimus solubilized with Marinomeds proprietary Marinosolv solubilization technology.